Ocugen Receives Green Light from Health Canada for Phase 3 Trial of Gene Therapy for Retinitis Pigmentosa
Author: Benzinga Newsdesk | August 26, 2024 07:09am
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a "No Objection Letter" to initiate the OCU400 Phase 3 liMeliGhT (pronounced "limelight") clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).
Posted In: OCGN